Lowering The 52 Week Low, Cellectis SA (Nasdaq:CLLS) Closing At $18.93

Cellectis SA (Nasdaq:CLLS)

December 13th, 2018
Cellectis SA fell $1.20 Thursday which equals a 5.96% decline, closing at $18.93. As well as the drop in value, Cellectis SA hit a new 52 week low of $18.71, breaking the previous low of $19.26 from earlier this month.

CLLS was outperformed by the rest of the Healthcare sector which went up 0.08%.

Market Sectors

The market sectors were mixed Thursday with a majority of the sectors trending up. Utilities saw the biggest increase of the day (0.88%), while Materials saw the biggest drop (1.13%). Healthcare has seen the biggest year-to-date gain at 11%. The biggest loss this year has been the Materials sector declining 15%.

Real Estate saw the biggest turnaround from its 5-day performance of -3.03%, as it went up 0.61%. Materials and Financials both saw turn arounds from their five day positive performance, Materials with a drop of 1.13%.

Sector Breakdown

  • Utilities went up with a 0.88% change.
  • Consumer Staples went up with a 0.69% change.
  • Real Estate went up with a 0.61% change.
  • Energy went up with a 0.36% change.
  • Information Technology went up with a 0.20% change.
  • Healthcare went up with a 0.08% change.
  • Communication Services went down with a -0.18% change.
  • Industrials went down with a -0.25% change.
  • Consumer Discretionary went down with a -0.44% change.
  • Financials went down with a -0.59% change.
  • Materials went down with a -1.13% change.

Cellectis is based in France. It was founded by André Choulika in 1999.

Cellectis SA Info

Cellectis S.A., a clinical stage biotechnological company, develops and sells immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer in France. The company operates through two segments, Therapeutics and Plants. Its lead product candidate is UCART19, an allogeneic T-cell product candidate for the treatment of CD19 expressing hematologic malignancies, which develop in acute lymphoblastic leukemia (ALL). The company’s products also comprise UCART123 for acute myeloid leukemia indications and blastic plasmacytoid dendritic cell neoplasm; UCARTCS1 for multiple myeloma (MM) indications; UCART22 for ALL; and UCART38 for T-ALL. In addition, it focuses on applying its gene-editing technologies to develop new generation plant products in the field of agricultural biotechnology. The company has strategic alliances with Pfizer Inc; Les Laboratoires Servier SAS; The University of Texas MD Anderson Cancer Center to research and develop novel cellular immunotherapies for patients suffering from various liquid tumors; and Cornell University to accelerate the development of a targeted immunotherapy for patients with acute myeloid leukemia, as well as a partnership agreement with the Wyss Institute for Biologically Inspired Engineering at Harvard University. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

All amounts in USD unless otherwise indicated

CLLS daily update
CLLS daily update

Media Gazelle Inc (MG), a Nevada Corporation, owns and operates the online brand US Tribune News. MG does not offer financial advise, and is not a registered broker/dealer/analyst/adviser, holds no investment licenses, and may not sell, offer to sell or offer to buy any security. MG’s market updates, news are not a solicitation or recommendation to buy, sell or hold securities. MG shall not be held liable for any investment losses you may incur by using the information provided, this includes you trading the stocks mentioned on our sites. We recommend you talk to a financial adviser before trading any securities or taking any action based upon information on this site. MG does not guarantee the accuracy of the article.